Drug intelligence / Profile preview

OQL023

Development stage: Preclinical
Lead developer: OnQuality Pharmaceuticals

Overview

**OQL023** is a preclinical drug candidate developed by OnQuality Pharmaceuticals for treating skin rashes induced by epidermal growth factor receptor (EGFR) inhibitors, a common dermatological side effect in cancer patients receiving EGFR-targeted therapies. It is part of the company's onco-dermatology pipeline aimed at improving quality of life for oncology patients by addressing therapy-induced skin toxicities. Details on its mechanism of action, formulation, or specific clinical data are not publicly available as of the latest reports.[1][7][11][15]

Beyond the preview

Go deeper on OQL023.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on OQL023.

Explore the full profile